Cullinan Therapeutics Inc.

12 clinical trials · Sponsor

Record	Firm	Date
A Phase 1b/2a Study of Velinotamig in Adults With Relapsed/Refractory ITP and wAIHA (NCT07738822)	Cullinan Therapeutics Inc.	2026-12-01
A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML Patients (NCT07722767)	Cullinan Therapeutics Inc.	2026-10-15
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease (NCT07041099)	Cullinan Therapeutics Inc.	2025-10-01
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Rheumatoid Arthritis (NCT06994143)	Cullinan Therapeutics Inc.	2025-05-19
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus (NCT06613360)	Cullinan Therapeutics Inc.	2025-01-21
A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma (NCT06381141)	Cullinan Therapeutics Inc.	2024-09-03
CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors (NCT06035744)	Cullinan Therapeutics Inc.	2023-12-12
A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL) (NCT05879744)	Cullinan Therapeutics Inc.	2023-05-31
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) (NCT05143996)	Cullinan Therapeutics Inc.	2021-11-18
A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (NCT05117476)	Cullinan Therapeutics Inc.	2021-10-29
A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer (NCT04036682)	Cullinan Therapeutics Inc.	2019-10-31
Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC) (NCT03682055)	Cullinan Therapeutics Inc.	2019-04-04

Track Cullinan Therapeutics Inc. automatically

Every clearance here is in the API, with alerts when new ones post.